Chronic disease therapies dominate top-selling drugs in Taiwan

Seventy percent of the 20 best-selling drugs in Taiwan are used to treat blood pressure, strokes and other chronic diseases, according to a survey conducted annually by the local newspaper, United Evening News. The best-selling drug, however, is used to treat hepatitis B.

Bristol-Myers Squibb's ($BMY) Baraclude (entecavir) got the top ranking for 2014, the survey said, selling nearly $63.7 million worth. Herceptin (trastuzumab), Genentech's breast-cancer treatment, was ranked second on the list, with the Novartis ($NVS) drug Glivec (imatinib) for leukemia coming in at third.

Pfizer's ($PFE) Lipitor (atorvastatin) led the chronic-disease category and ranked fourth on the best-seller list. It was followed by AstraZeneca's ($AZN) Crestor (rosuvastatin) at fifth and Sanofi's ($SNY) Plavix (clopidogrel) at sixth.

Some of the more expensive drugs on the market also sold better during 2014, the survey showed, with Shire's ($SHPG) Replagel (agalsidase), which is used to treat the rare Fabry disease at a cost of more than U.S. $3,000 a shot, making the top-20 list.

An oral version of hepatitis C drugs is expected to reach Taiwan's market soon, according to one analyst. At nearly USD $80,000 per regimen, it will probably become the costliest drug immediately.

- here's the United Evening News story (in Chinese)
- here's the China Post's take

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.